Medison to market uniQure's Glybera in Israel for treatment of lipoprotein lipase deficiency

uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, and Medison Pharma Ltd., Israel's leading international healthcare marketing group, today announced an exclusive distribution agreement under which Medison will market Glybera®, uniQure's gene therapy product for the treatment of lipoprotein lipase deficiency (LPLD), in Israel and the Palestinian Authority. Medison will also be responsible for obtaining regulatory approval for Glybera in both territories. Financial terms of the agreement have not been disclosed. Glybera is approved in the EU as a treatment for LPLD, a potentially life-threatening, orphan metabolic disease that results in patients' inability to process fat in the blood after a meal.

"Glybera represents an exciting opportunity for Medison to continue its leadership in offering new innovative treatments in Israel," stated Meir Jakobsohn, Founder and CEO of Medison.

"After carefully evaluating different commercialization strategies for Glybera in the Israeli market, we have concluded that partnering Glybera allows us to optimize the value of the asset as we continue to develop our pipeline," said Jörn Aldag, Chief Executive Officer. "Medison has a well-established and significant commercial organization in Israel with a proven track record in successfully marketing specialty products. Through this partnership Glybera will be available to LPLD patients in Israel and the Palestinian Authority sooner than otherwise possible. uniQure remains focused on the advance of Glybera toward the initiation of the regulatory process in the USA this year, as well as the further development of our candidate gene therapies currently in the clinic."


Medison Pharma


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
You might also like... ×
Higher maternal blood pressure linked to placental gene modifications